-

06:21:58 PM

HSTO Stock News

HSTO - Histogen Inc

01/18/23 2:02 PM

Nasdaq : HSTO

covid-19low float

Amerimmune LLC Maintains Intellectual Property on the COVID-19 Related Use of Caspase Inhibitors as a Result of Histogen Inc. Led Arbitration

Amerimmune LLC is a translational medicine biotechnology firm focused on discovery and rapid development of novel therapies for diseases, including COVID-19. On October 27, 2020, Amerimmune LLC entered into a development Agreement with Histogen Inc. to jointly develop Emricasan as a potentially promising treatment for COVID-19. Histogen Inc. filed for...

RHEA-AI

neutral

01/03/23 4:05 PM

Nasdaq : HSTO

managementlow float

Histogen Hires Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing its pan-caspase and caspase selective inhibitors as

RHEA-AI

neutral

11/10/22 4:15 PM

Nasdaq : HSTO

earningslow float

Histogen Reports Third Quarter 2022 Financial Results and Provides Business Update

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory

RHEA-AI

very positive

08/11/22 4:05 PM

Nasdaq : HSTO

earningslow float

Histogen Reports Second Quarter 2022 Financial Results and Provides Business Update

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and

RHEA-AI

very positive

07/27/22 4:05 PM

Nasdaq : HSTO

conferencesearningslow float

Histogen to Report Second Quarter 2022 Financial Results and Provide Business Update

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced

RHEA-AI

neutral

07/14/22 4:05 PM

Nasdaq : HSTO

low float

Histogen Announces Closing of $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, announced today

RHEA-AI

neutral

07/12/22 11:40 AM

Nasdaq : HSTO

low float

Histogen Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, announced today

RHEA-AI

neutral

06/01/22 4:00 PM

Nasdaq : HSTO

low float

Histogen Announces 1-for-20 Reverse Stock Split

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced

RHEA-AI

neutral

05/17/22 4:05 PM

Nasdaq : HSTO

conferenceslow float

Histogen to Present at the H.C. Wainwright Global Investment Conference

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that

RHEA-AI

neutral

05/12/22 4:05 PM

Nasdaq : HSTO

earningslow float

Histogen Reports First Quarter 2022 Financial Results and Provides Business Update

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused

RHEA-AI

very positive

1 2 3 4 5 6 7 8 Next

HSTO Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.histogen.com
CeoSteven Mento
Security nameHistogen Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees19
Tags
- Health Technology
- Biotechnology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address10655 Sorrento Valley Road
Address2Suite 200
StateCalifornia
CitySan Diego
Zip92121
CountryUS
Phone18585263100

About Histogen Inc

Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Histogen's innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen's proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair.